Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $42.02.Don't Miss Our ...

Shares of Verona Pharma stock opened at $41.22 on Tuesday. The stock has a market capitalization of $3.32 billion, a price-to-earnings ratio of -21.47 and a beta of 0.46. The company has a debt-to ...

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual ...

While not every stock... Verona Pharma (VRNA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently ...

4. Verona’s Ohtuvayre (ensifentrine) for COPD Just as Verona Pharma secured the FDA nod to market inhalable COPD drug Ohtuvayre in June, its commercial prospects seemed to improve markedly. While ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

European equities traded in the US as American depositary receipts were trending slightly lower late Monday morning, declining 0.16% to 1,278.01 on the S&P Europe Select ADR Index. From continental ...

Verona Pharma has claimed FDA approval for its chronic obstructive pulmonary disease (COPD) drug ensifentrine, which has been tipped as a future blockbuster. The first-in-class dual ...

Sanofi S.A. Part Cert 0.06% €8.19M ...